Qualigen Therapeutics, Inc. Overview
Pro stress-test →Qualigen Therapeutics was a clinical-stage biotechnology company focused on developing novel therapeutics for cancer and infectious diseases, operating through (November 2025) before undergoing a strategic transformation. The company maintained FastPack®, an FDA-approved diagnostic platform generating over $100 million in historical commercial sales. As of November 2025, the company rebranded to AIxCrypto Holdings, Inc., pivoting toward crypto assets and Web3 strategies.
Strategic Profile
Pro stress-test →Historically, Qualigen positioned itself as a nanoparticle-based therapeutic developer with dual focus on oncology (ALAN, RAS-F programs) and infectious disease programs (AS1411 for COVID-19). The company leveraged partnerships with the University of Louisville and maintained a diagnostic revenue stream through FastPack licensing agreements, notably with Sekisui Diagnostics (Japan). The November 2025 rebranding signals a fundamental strategic departure from therapeutics.
Competitive Landscape
Pro stress-test →As a historical oncology-stage biotech, Qualigen competed with clinical-stage cancer therapy developers and diagnostic testing companies. Prior competitors in diagnostics included point-of-care testing providers; in oncology, competitors were nucleolin-targeting and RAS-inhibitor developers. Post-rebranding, competitive positioning shifted entirely to crypto asset managers.
Industry Context
Qualigen Therapeutics, Inc. operates in Clinical-stage oncology therapeutics.
Key facts
Headquarters: Carlsbad, California · Employees: 11-50 · Revenue: N/A · Market cap: $6.5M (as November 2025, pre-rebranding)